CannTab Therapeutics featured on the Midas Letter
Month: September 2018
FSD Pharma Receives First Delivery of Cantabb Equipment with a Capacity to Manufacture Approx. 1,500,000 Tablets Per Day
TORONTO, Sept. 25, 2018 /CNW/ – FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that the Company has received its first delivery of manufacturing equipment at its Cobourg plant from Canntab Therapeutics Limited (CSE:PILL) (“Canntab”), a leader in the rapidly growing cannabis pill market. The manufacturing equipment consists of a fully GMP High output Tablet press capable of pressing more than 1,500,000 tablets per day, as well as blending machinery, large scale process and drying equipment and packaging equipment.
FSD Pharma and SciCann Therapeutics Launch Cardiovascular Research Program in Tel Aviv University
TORONTO, Sept. 23, 2018 FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is pleased to announce the launch of a comprehensive sponsored research program in Tel Aviv University together with its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann”), focused on the cardiovascular disease field. The new research program is aimed at the development of novel and proprietary cannabinoid-based treatments for the prevention and treatment of atherosclerosis, the underlying factor for most cases of stroke and cardiac stenosis events in the western world.
FSD Pharma Inc. Announces $7.5 Million Dollar at $1 Per Share Investment as Part of Existing Strategic Alliance with Auxly Cannabis Group Inc.
TORONTO, Sept. 20, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) is pleased to announce that pursuant to the approved construction and development budget announced on July 3, 2018 (Link), Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly”) has made an equity investment into the Company at $1.00 per Class B Subordinate Voting Share for total proceeds of $7.5 million. No fees were paid to brokers in connection with the transaction.
FSD Pharma Signs Collaboration and Profit Sharing Agreement with Canntab for Production and Market of Oral Dose Delivery Platforms
TORONTO, Sept.18, 2018 /PRNewswire/ – FSD Pharma Inc. (CSE: HUGE) (OTC :FSDDF ) (FRA: 0K9) (“FSD Pharma” or the “Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that it has signed a definitive collaboration and profit sharing agreement (the “Agreement”) with Canntab Therapeutics Limited (CSE:PILL) (“Canntab”), a leader in the rapidly growing cannabis pill market, effective September 17, 2018. Under the terms of the Agreement, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the “License”), and will provide Canntab with space at its facility (the “FSD Facility”), which is located
FSD Pharma joins Snipp’s Cannabis Marketing Resource Center
CSE: HUGE OTC: FSDDF FRA: 0K9 TORONTO, Sept. 17, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) today announced that it has joined the Cannabis Marketing Resource Center (“CMRC”) provided by Snipp Interactive Inc. (“Snipp”) (OTCQB: SNIPF; TSX-V: SPN), a global provider of digital marketing promotions, rebates and loyalty solutions. FSD has now joined some of the largest licensed producers in Canada that currently use the CMRC and the technology solutions provided by Snipp.
Bird River Resources Announces Conditional approval from the CSE
Winnipeg, Manitoba (FSCwire) – Bird River Resources Inc. (CSE:BDR) (the “Company”) is pleased to announce that further to its news release dated June 5, 2018 the Company has received conditional approval from the Canadian Securities Exchange (the “CSE”) for its draft comprehensive CSE Form 2A 2018 Listing Statement (“Listing Statement”) and lifting of the temporary trading halt on the Company’s shares. The draft Listing Statement has been prepared and filed pursuant to the request of the CSE for further information concerning the Company’s acquisition of High Point Oil Inc.